FDA Advisory Committee Recommends Approval Of Alirocumab Injection For Patients With Hypercholesterolemia
Sunday, June 14, 2015 - 21:50
in Health & Medicine
The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent (alirocumab) Injection for patients with hypercholesterolemia. read more